Preformulation studies to aid in the development of a ready-to-use injectable solution of the antitumor agent, topotecanKEARNEY, A. S; PATEL, K; PALEPU, N. R et al.International journal of pharmaceutics. 1996, Vol 127, Num 2, pp 229-237, issn 0378-5173Article

Oral topotecan given once or twice daily for ten days : A phase I pharmacology study in adult patients with solid tumorsGERRITS, C. J. H; BURRIS, H; FIELDS, S et al.Clinical cancer research. 1998, Vol 4, Num 5, pp 1153-1158, issn 1078-0432Article

Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecanVAN ERP, Nielka P. H; BAKER, Sharyn D; MING ZHAO et al.Clinical cancer research. 2005, Vol 11, Num 21, pp 7800-7806, issn 1078-0432, 7 p.Article

Irinotecan in combination with new agentsVANHOEFER, U; ROUGIER, P; BORNER, M et al.European journal of cancer. Supplement (1990). 2004, Vol 2, Num 7, pp 14-20, issn 1359-6349, 7 p.Conference Paper

Metabolism of irinotecan (CPT-11) by human hepatic microsomes : Participation of cytochrome P-450 3A and drug interactionsHAAZ, M.-C; RIVORY, L; RICHE, C et al.Cancer research (Baltimore). 1998, Vol 58, Num 3, pp 468-472, issn 0008-5472Article

A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumorsFAKIH, Marwan G; PENDYALA, Lakshmi; SMITH, Patrick F et al.Clinical cancer research. 2006, Vol 12, Num 4, pp 1237-1244, issn 1078-0432, 8 p.Article

Delta-24 increases the expression and activity of topoisomerase i and enhances the antiglioma effect of irinotecanGOMEZ-MANZANO, Candelaria; ALONSO, Marta M; FUEYO, Juan et al.Clinical cancer research. 2006, Vol 12, Num 2, pp 556-562, issn 1078-0432, 7 p.Article

Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly scheduleGARCIA, Agustin A; PUJARI, Mahesh; JEFFERS, Susan et al.Cancer chemotherapy and pharmacology. 2005, Vol 56, Num 1, pp 75-82, issn 0344-5704, 8 p.Article

Serum Cystatin C is a better marker of topotecan clearance than serum creatinineHOPPE, Antje; SERONIE-VIVIEN, Sophie; THOMAS, Fabienne et al.Clinical cancer research. 2005, Vol 11, Num 8, pp 3038-3044, issn 1078-0432, 7 p.Article

Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patientsROUITS, Elisabeth; BOISDRON-CELLE, Michèle; DUMONT, Agnès et al.Clinical cancer research. 2004, Vol 10, Num 15, pp 5151-5159, issn 1078-0432, 9 p.Article

Concurrent radiation therapy and Irinotecan in stage IIIB cervical cancerSUNTORNPONG, Nan; CHANSILP, Yaowalak; PATTARANUTAPORN, Pittayapoom et al.Chot Mai Het Thang Phaet. 2003, Vol 86, Num 5, pp 430-435, issn 0125-2208, 6 p.Article

High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasmaSCHOEMAKER, Nadja E; ROSING, Hilde; JANSEN, Sindy et al.Therapeutic drug monitoring. 2003, Vol 25, Num 1, pp 120-124, issn 0163-4356, 5 p.Article

Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecinHANIOKA, N; OZAWA, S; JINNO, H et al.Xenobiotica (London. Print). 2001, Vol 31, Num 10, pp 687-699, issn 0049-8254Article

A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4KIMIE SAI; KANIWA, Naoko; OZAWA, Shogo et al.Drug metabolism and disposition. 2001, Vol 29, Num 11, pp 1505-1513, issn 0090-9556Article

Population pharmacokinetic model for topotecan derived from phase I clinical trialsGALLO, J. M; LAUB, P. B; ROWINSKY, E. K et al.Journal of clinical oncology. 2000, Vol 18, Num 12, pp 2459-2467, issn 0732-183XArticle

Five days of oral topotecan (Hycamtin®), a phase I and pharmacological study in adult patients with solid tumoursGERRITS, C. J. H; BURRIS, H; VERWEIJ, J et al.European journal of cancer (1990). 1998, Vol 34, Num 7, pp 1030-1035, issn 0959-8049Article

Secondary response of ovarian tumors to topotecan treatmentDUNTON, C. J; NEUFELD, J; CARLSON, J. A et al.Gynecologic oncology (Print). 1998, Vol 69, Num 3, pp 258-259, issn 0090-8258Article

The use of topoisomerase I inhibitors in multiple myelomaKRAUT, E. H; RONG JU; MULLER, M et al.Seminars in hematology. 1998, Vol 35, Num 3, pp 32-38, issn 0037-1963, SUP4Article

Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patientsGUPTA, E; MICK, R; RAMIREZ, J et al.Journal of clinical oncology. 1997, Vol 15, Num 4, pp 1502-1510, issn 0732-183XArticle

Limited sampling model for area under the concentration time curve of total topotecanMINAMI, H; BEIJNEN, J. H; VERWEIJ, J et al.Clinical cancer research. 1996, Vol 2, Num 1, pp 43-46, issn 1078-0432Article

Bioavailability and pharmacokinetics of oral topotecan : a new topoisomerase I inhibitorSCHELLENS, J. H. M; CREEMERS, G. J; BEIJNEN, J. H et al.British journal of cancer. 1996, Vol 73, Num 10, pp 1268-1271, issn 0007-0920Article

Les topoisomérases: intérêt thérapeutique = Topoisomerases. Therapeutic interestFAURE, P; MADELAINE, I.Annales pharmaceutiques françaises. 1996, Vol 54, Num 1, pp 40-44, issn 0003-4509Article

Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urineLOKIEC, F; CANAL, P; GAY, C et al.Cancer chemotherapy and pharmacology. 1995, Vol 36, Num 1, pp 79-82, issn 0344-5704Article

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrheaABIGERGES, D; ARMAND, J.-P; CHABOT, G. G et al.Journal of the National Cancer Institute. 1994, Vol 86, Num 6, pp 446-449, issn 0027-8874Article

Liposomalization of SN-38 as active metabolite of CPT-11SADZUKA, Yasuyuki; TAKABE, Hiroyuki; SONOBE, Takashi et al.Journal of controlled release. 2005, Vol 108, Num 2-3, pp 453-459, issn 0168-3659, 7 p.Article